Loading
PDBj
メニューPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7LAD

Clobetasol propionate bound to CYP3A5

7LAD の概要
エントリーDOI10.2210/pdb7lad/pdb
分子名称Cytochrome P450 3A5, PROTOPORPHYRIN IX CONTAINING FE, Clobetasol propionate, ... (4 entities in total)
機能のキーワードcytochrome p450, cyp3a5, membrane protein
由来する生物種Homo sapiens (Human)
タンパク質・核酸の鎖数1
化学式量合計56153.22
構造登録者
Buchman, C.D.,Miller, D.,Wang, J.,Jayaraman, S.,Chen, T. (登録日: 2021-01-06, 公開日: 2021-10-27, 最終更新日: 2023-10-18)
主引用文献Wang, J.,Buchman, C.D.,Seetharaman, J.,Miller, D.J.,Huber, A.D.,Wu, J.,Chai, S.C.,Garcia-Maldonado, E.,Wright, W.C.,Chenge, J.,Chen, T.
Unraveling the Structural Basis of Selective Inhibition of Human Cytochrome P450 3A5.
J.Am.Chem.Soc., 143:18467-18480, 2021
Cited by
PubMed Abstract: The human cytochrome P450 (CYP) CYP3A4 and CYP3A5 enzymes metabolize more than one-half of marketed drugs. They share high structural and substrate similarity and are often studied together as CYP3A4/5. However, CYP3A5 preferentially metabolizes several clinically prescribed drugs, such as tacrolimus. Genetic polymorphism in makes race-based dosing adjustment of tacrolimus necessary to minimize acute rejection after organ transplantation. Moreover, the differential tissue distribution and expression levels of CYP3A4 and CYP3A5 can aggravate toxicity during treatment. Therefore, selective inhibitors of CYP3A5 are needed to distinguish the role of CYP3A5 from that of CYP3A4 and serve as starting points for potential therapeutic development. To this end, we report the crystal structure of CYP3A5 in complex with a previously reported selective inhibitor, clobetasol propionate (CBZ). This is the first CYP3A5 structure with a type I inhibitor, which along with the previously reported substrate-free and type II inhibitor-bound structures, constitute the main CYP3A5 structural modalities. Supported by structure-guided mutagenesis analyses, the CYP3A5-CBZ structure showed that a unique conformation of the F-F' loop in CYP3A5 enables selective binding of CBZ to CYP3A5. Several polar interactions, including hydrogen bonds, stabilize the position of CBZ to interact with this unique F-F' loop conformation. In addition, functional and biophysical assays using CBZ analogs highlight the importance of heme-adjacent moieties for selective CYP3A5 inhibition. Our findings can be used to guide further development of more potent and selective CYP3A5 inhibitors.
PubMed: 34648292
DOI: 10.1021/jacs.1c07066
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.65 Å)
構造検証レポート
Validation report summary of 7lad
検証レポート(詳細版)ダウンロードをダウンロード

227111

件を2024-11-06に公開中

PDB statisticsPDBj update infoContact PDBjnumon